Nondopaminergic Pathology, Treatments, and Trials in Parkinson’s Disease This issue of Neura features a review of the nondopaminergic aspects of Parkinson's disease, including pathology, treatment, and clinical trials. Other articles include a discussion on differentiating multiple sclerosis from other demyelinating disorders, a report from the 38th Annual Society for Neuroscience Meeting, and a Highlights section that summarizes several articles published recently in the literature. |
 CME Nondopaminergic Pathology, Treatments, and Trials in Parkinson’s Disease
Evidence shows that nondopaminergic systems are affected by Parkinson’s disease (PD) and that disabilities seen in late-stage PD are not responsive to dopaminergic replacement therapies. This article focuses on the nonmotor symptoms of PD (psychoses, cognitive disorders, sleep disorders, and autonomic, gastrointestinal, and sensory symptoms) and also reviews nondopamine-based therapies that are in development.
CME Differentiating MS From Other Demyelinating Disorders
Multiple sclerosis (MS) can be difficult to diagnose, as many other conditions mimic the symptoms of MS, and these must be excluded in order to make an accurate MS diagnosis. This article focuses on the consensus approach developed by the International Panel of MS Experts.
Neuroscience 2008 Round-Up
A report from the 38th Annual Meeting of the Society for Neuroscience (SfN) features findings from the forefront of neurological research. The report includes research covering cognitive impairment and Aβ levels in Alzheimer’s Disease (AD); the physiologic effects of chronic stress on the brain; data from animal models demonstrating that nicotine prevents dopaminergic deficits before, but not after, nigrostriatal insult (like that seen in PD); and a study assessing the effects of different exercise regimens in a mouse model of amyotrophic lateral sclerosis (ALS).
Highlights From the Literature
Highlights from recent articles about dementia include a tightening genetic link between late-onset AD and apolipoprotein E (APOE) and results from the dementia antipsychotic withdrawal trial (DART-AD). An additional highlight addresses radiologically isolated syndrome and its possible implications in the development of MS.
Patient Tear-Out: Your MS Management, Your Way
Neura provides a summary to patients about the recent developments in disease-modifying therapies for MS. These advances include a new treatment formulation, thinner needles for the administration of 2 other drugs, and important safety information for MS therapies.
|
